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Abstract
Background: Radiotherapy is one of the most important treatments of primary and metastatic brain tumors.
Unfortunately, it can involve moderate to severe complications among which leukoencephalopathy is very
frequent and implies cognitive deficits such as memory, attention and executive dysfunctions. However, the
incidence of this complication is not well established and the risk factors and process are poorly understood.
The main objective of the study is to improve knowledge on radio-induced leukoencephalopathy based on
pluridisciplinar approaches combining cognitive, biologic, imagery and dosimetric investigations.
Method/Design: The EpiBrainRad study is a prospective cohort study including newly diagnosed high grade
gliomas patients treated by radiotherapy and concomitant-adjuvant temozolomide chemotherapy. Patients are
included between their surgery and first day of radio-chemotherapy, and the follow-up lasts for 3 years after
treatment. Cognitive functioning assessments, specific blood biomarkers measures and magnetic resonance
imagery are performed at different moment during the follow-up, and a specific dosimetric assessment of
organs involved in the beam fields is performed. Firstly, leukoencephalopathy incidence rate will be estimated
in this population. Secondly, correlations between cognitive impairments and dosimetry, biomarkers ranges
and anomalies on imagery will be analyzed in order to better understand the onset and evolution of cognitive
decrement associated with radiotherapy. Furthermore, a new cognitive test, quickly and easily performed, will
be studied to determine its sensibility to detect leukoencephalopathy decrement.
Discussion: With an original multidisciplinary approach, the EpiBrainRad study aims to improve knowledge on
radio-induced leukoencephalopathy in order to improve its early diagnosis and prevention. The main challenge
is to preserve quality-of-life after cancer treatments which imply to study the incidence of radiation-induced
complications and their associated risk factors.
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Background
Radiotherapy is one of the most important treatments of
metastatic and primary brain tumors of which 60 % are
high grade glioblastomas. With the recent development
of modern irradiation techniques, survival of patients
has increased and mid- to long-term side effects became
more visible, such as neurologic complications [1].
Among these complications, leukoencephalopathy seems
to be the most frequent. It is characterized by a progres-
sive and diffuse demyelination, an axonal loss and vascu-
lar lesions [2]. Consequences of leukoencephalopathy
involve cognitive deficits which dramatically reduce the
patient’s quality-of-life [3–5]. Thus, since the last few
years, the neuropsychological status represents an im-
portant issue in clinical trials as well as in individual out-
comes [6]. Long-term memory, information speed
processing, attention and executive functions are recog-
nized to be the most sensitive functions to be affected
by radiations [2, 7–10]. However, there is no consensus
to describe the main evolution of cognitive decrement
following radiotherapy because of important differences
in studies’ protocols (assessment time, decrement defini-
tions, material). The radiation-induced leukoencephalo-
pathy incidence is thus difficult to estimate precisely and
varies from 30 to 50 % [10, 11] according to the length
of follow-up. Moreover, available studies are often retro-
spective which may induce bias and based on small sam-
ples which limits statistical robustness of results.
Although several risk factors of neurotoxic complica-
tion have been identified such as patient’s age, tumor
location, total dose of radiation, fractionation, field size
[2, 9, 12], the pathophysiology of radiation-induced
neurotoxicity is still poorly understood. It could involve
inflammation, blood barrier disruption, vascular lesion,
demyelination, radio-necrosis and edema [2, 9]. Until
now, it is impossible to precisely estimate at individual
level the risk for a patient to develop this neurotoxic
complication [13, 14]. Some individual risk factor such
as cardio-vascular diseases (hypertension, diabetes),
smoking, old age [15, 16] seem implicated in leukoen-
cephalopathy. Assessment of the impact of both indi-
vidual risk factors and treatment toxicity requires to
study a large group of patient with prospective collec-
tion of accurate data and follow-up.
From a biological point of view, biological mechanisms
of the initiation and progression of cognitive impaire-
ments is not well known. However, specific biomarkers
predictive of the cognitive impairments in this popula-
tion would help in screening patients at risk of neuro-
toxicity. Currently, biomarkers of neurotoxicity have
been poorly studied. Thus, several markers deserve to be
explored such as the S-100B protein known to be a
marker of traumatic cerebral lesion, neurodegenerative
diseases and aggressive gliomas [17], specific isoprostanes
(as 8,12-iso-iPF2α-VI) implicated in the oxidative/nitrate
stress in neurodegenerative diseases [18] and homocystein
which plasma concentration has been associated with poor
memory performances in old individuals [19]. Furthermore,
new biomarkers seems to be potentially very interesting. In-
deed, micro RNA and microparticules have been identified
as potential biomarkers of neurological defects [20, 21].
Then the strategy proposed is to test classical and new bio-
markers in order to individualize those, which could be ac-
curate for the screening of patients at risk of cognitive
impairments.
At last, assessment of cognitive impairment is difficult
because the exploration of cognitive side effects is not
systematic and often depends on patients’ complaints
and clinicians’ sensibility to this aspect. A formal neuro-
psychological assessment can’t be performed in routine,
as often as it should be for an adapted follow-up of brain
tumor patients. Indeed, it is time consuming, needs ex-
pert professionals and validated material, and conse-
quently it is not easily implemented in most medical
center. A new tool for exploration of cognitive deficits is
the Computerized Speed Cognitive Test (Legal deposit:
IDDN.FR.001.180018.000.S.P.2014.000.31230) (CSCT) [22].
The CSCT was first developed to assess information speed
processing in multiple sclerosis. Because it presents a low
learning-effect and focuses on a cognitive characteristic
often impaired in neuro-oncologic population, it could be
used to detect a cognitive deterioration during repeated
medical visits, and thus be used as an alarm to start a more
extensive formal assessment. Then, it is suitable for the
follow-up of a cohort of patients treated for brain tumor
and allows to give quick and reliable information on cogni-
tive impairment, compatible with the usual clinical follow-
up of the patients.
Objectives
The purpose of the EpiBrainRad study is to establish a
cohort of patients treated with radiotherapy for a high
grade glioma.
The main objective is to estimate the cognitive impair-
ment incidence related to radio-induced leukoencepha-
lopathy in this population.
Secondary objectives are:
– To study the impact of associated risk factors on
leukoencephalopathy development, including
individual factors and treatment.
– Biologic markers of neurologic degradation will be
studied to evaluate the correlations between
cognitive impairments and biological abnormalities.
– Specific organs dosimetry (such as hippocampus,
temporal lobes, corpus callosum, peri-ventricular
white matter, posterior fossa) correlated with radiologic
abnormalities on magnetic resonance imagery (MRI)
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and clinical symptoms will be analyzed to better
understand the evolution of radio-induced
leukoencephalopathy.
– Finally, the assessment of the sensibility and
specificity of a quick cognitive test, the
Computerised Speed Cognitive Test [22], to detect
a cognitive decrement during the follow up of the
patients.
Methods/Design
Study design and patient selection
The EpiBrainRad study is an observational prospective
cohort. Patients’ recruitment takes place at Hôpital de la
Pitié-Salpêtrière (Paris, France) and Centre de Lutte
Contre le Cancer Paul Strauss (Strasbourg, France) for
2 years and each patient is followed during 3 years. The
cohort includes newly-diagnosed adults treated for a
high grade glioma according to the procedure described
by Stupp et al. [23]. According to patient’s age, the
radiotherapy regiment can be modified to 40 gy in 15
fractions to ensure a better tolerance in elders [24]. In-
clusion and exclusion criteria are listed in Table 1. Data
are prospectively including clinical features, MRI images
and results, blood samples, dosimetry and cognitive as-
sessments during the usual medical follow-up.
Ethical approval
This study has received ethical approval from the Comité
de Protection de la Personne de Paris VI Ile de France in
December 2014 (ID: CPP/132-14) and from National
Agency for Medical and Health products Safety (Refer-
ence: 2014-A01697-40). The Clinical Trial Registration
Information is available at http://www.clinicaltrials.gov
(Unique identifier NCT02544178). Participants enrolled
in the study provide their written informed consent.
Study endpoints
The primary endpoint is the reduction in performance
on cognitive tests defined as follows: After exclusion of
local recurrence, decreased detailed neuropsychological
assessment score compared to the patient's baseline
score before radiotherapy for at least 2 cognitive
domains.
Secondary endpoints are:
– Differences in biomarkers’ concentration between
the measurements before RT and: at the end of the
RT, RT + 4 weeks, RT + 12 months and RT +
36 months.
– Changes in MRI images compared to the baseline
imaging.
– Correlations between dosimetry, cognitive decay and
MRI abnormalities onset after RT.
Procedures
Figure 1 gives an overview of the study flowchart. Pa-
tients’ inclusion occurs after surgery and before radio/
chemotherapy (Baseline). At this time, individual infor-
mation including demographic information, medical
background and tumor characteristic are collected.
Every 3 months, once the MRI of the patient is done, a
medical visit occurs during which a short cognitive as-
sessment is performed (the CSCT).
Cognitive tests, scales and questionnaires used for the
formal assessment are listed in Table 2. An extensive
evaluation lasting 2 h is performed with a trained neuro-
psychologist, followed by self-reported and caregiver-
reported scales and questionnaires. The explored do-
mains are intellectual efficiency, general functioning,
verbal and visual episodic memory, attention, executive
functioning, language, visuospatial and visuoconstructive
abilities, mood, fatigue, quality-of-live, subjective com-
plaints and autonomy. The formal assessment occurs at
baseline and yearly after radiotherapy. In case of CSCT
score decrement during follow-up the next yearly formal
assessment is performed earlier. CSCT decrement is de-
fined as a loss of 1 standard deviation compared to base-
line (given its low learning-effect and good stability in
controls [22]), during two consecutive assessments. The
necessity of detecting a decrement during two visits per-
mits to insure that a variation in score is not due to a
transitory cause like an infection or fatigue, which is re-
versible and not linked to leukoencephalopathy. This
procedure will allow to study the nature, course and in-
cidence of cognitive decrement following radiotherapy in
this population. At baseline and during the follow-up,
the CSCT will be compared to the formal cognitive as-
sessment to study its sensibility to detect impairments in
this context.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Newly diagnosed grade III or IV glioma
• Age ≥ 18
• Treated by radiotherapy and concomitant-adjuvant Tomozolomide
as described by Stupp et al. [23] or with an abbreviated course of
radiotherapy in elders patients [24]
• Treatment and clinical follow-up performed at Hôpital de la
Pitié-Salpêtrière (Paris, France) or Centre de lute contre le cancer
Paul Strauss (Strasbourg, France)
• History of other CNS tumor
• History of neurologic and/or psychiatric disease involving cognitive
impairments (TBI, Stroke, mood and personality disorders…)
• Insufficient understanding of French language
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Baseline and trimensual MRI during the medical
follow-up are used for extra analysis in order to study
white matter abnormalities and cortical atrophy. More-
over, tumor response or progression will be assessed by
the Response Assessment in Radio-Oncology working
group (RANO) Criteria [25]. The white matter lesion
quantification will follow the procedure described by
Wahlund et al. [26] using a 4 points scale (0: no lesion;
1: focal lesions; 2: beginning confluence of lesion; 3: dif-
fuse involvement of the entire region). The cortical atro-
phy quantification will follow the procedure described
by Pasquier et al. [27] using a 4 points scale (0: absence
of atrophy; 1: mild atrophy; 2: moderate atrophy; 3: se-
vere atrophy). White matter lesion and cortical atrophy
is assessed for all key region listed in Table 3. A double
blind lecture of the MRI will be done in order to quan-
tify these anomalies. Radiological outcomes will then be
correlated with cognitive outcomes.
The need for a biological marker of cognitive disorders
has proven to be urgent, both for diagnosis and for
monitoring of the diseases. Among the advantages that
such markers may bring, we emphasize the possibility of
early and even preclinical diagnosis of the disease with
the subsequent correct treatment of disease by the med-
ical team. Biomarkers for cognitive impairment have
been an issue in recent years. The value of a variety of
these markers, like amyloid beta or tau, has been evalu-
ated and discussed [28]. Besides proteins, microRNAs
have also demonstrated their potential as non-invasive
biomarkers from blood and serum for a wide variety of
human pathologies [29]. A deregulation of microRNA
expression might be involved in neurological dysfunction
or neurodegenerative processes. A recent serum profil-
ing of Alzheimer disease patients provided evidence that
expression changes of circulating miRNAs may be
valuable biomarkers for this neurological disease [20].
In addition, microparticles have been implicated to
have pathological roles in many diseases such as
Alzheimer’s disease. The consensus among recent
studies is that increased levels of specific types of mi-
croparticles in plasma may represent reliable bio-
logical markers for the onset and progression of
central nervous system diseases [30].
Consequently, plasmatic classical biomarkers as S-100B
protein, isoprostane 8,12-iso-iPF2α-VI, homocysteine and
new ones, as micro RNA and microparticules (see Table 4)
will be sampled in blood at baseline, 4 weeks, 12 months
and 36 months after the end of radiotherapy. These bio-
markers could be potential blood predictors of cognitive
impairments [17, 19–21] and thus their concentration evo-
lution after radiations will be analyzed. Additional blood
sample tubes are stored to constitute a biological collection
for future investigations about others biomarkers.
Finally, histograms of dose-volumes (HDV) of specific
organs and areas are collected to study the relation be-
tween the radiation doses received by these structures
and the cognitive decrements observed. Indeed, some
authors showed correlations between specific structures
and cognitive performances [31, 32] but few data are
available and thus these relations need to be explored.
More, dosimetry is compared with onset of abnormal-
ities on MRI to improve knowledge about radio-induced
leukoencephalopathy process. Structures prospectively
investigated are listed in Table 3.
Statistical analysis
Sample size consideration
The main objective being to estimate the incidence of
occurrence of neurological complications in the cohort,
with an expected proportion P varying from 0.2 to 0.5,
for a confidence level of 95 %, with alpha risk of 5 %, the
number of subjects to be included varies between 246
Fig. 1 Study procedure
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and 384. Given the risk of relatively early death related
to the disease, the inclusion of 400 patients will provide
good statistical power for this purpose.
Planned analysis
The combination of data from four axes (Clinical Epi-
demiology, Dosimetry, Biomarkers and Radiobiology)
will give the opportunity to precisely analyze the links
between cognitive impairments and changes in bio-
markers depending on the precise dose absorbed at dif-
ferent brain areas during radiotherapy brain cancer.
Descriptive statistics (means, standard deviations, per-
centages and 95 % confidence intervals) will be used to
describe the distribution of subjects according to each of
the terms of the variables studied. Analyses of variance
to one or more classification criteria will be used to
compare the means of continuous quantitative variables.
Chi-square test or Fisher exact test will be used to com-
pare the distribution of nominal discrete variables and /
Table 2 Tests and questionnaires used for the cognitive, mood and behavioral assessment
Domain Tests, scales and questionnaires
Cognitive assessment
Intellectual efficiency National Adult Reading Test (French version) [38]
General functioning Mini Mental State Examination [39]
Montreal Cognitive Assessment [40]
Dementia Rating Scale-2 [41]
Verbal episodic memory RLRI-16 (Adaptation of the Grober-Buschke test) [42]
Visual episodic memory Rey-Osterrieth Complex Figure [43]
Executive functions and Attention Digit Span forward [44]
Digit Span backward [44]
Letter-number sequencing [44]
Categorical and phonetic word fluency [45, 46]
Trail Making Test [45, 46]
Computerized Speed Cognitive Test [22]
Stroop color-word Test [45, 46]
Langage Boston Naming Test [47]
Token Test [48]
Visuospatial and visuoconstructive functions Rey-Osterrieth Complex Figure [43]
Self-reported Scales
Mood Anxiety questionnaire of Goldberg [49]
Center for Epidemiologic Study Depression Scale [50]
Fatigue FACIT Fatigue Scale [51]
Memory complaint MacNair and Khan questionnaire [52, 53]
Quality-of-life EORTC QLQ-C30 [54]
EORTC QLQ-BN20 [55]
Care-giver-reported Scales
Dysexecutive syndrome ISDC [45, 46]
Autonomy EIADL [56]




Frontal lobes * *





Brain Stem * *
Hippocampus *
Corpus Callosum *
Periventricular white matter *
* anatomical region investigated
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or ordinal. All tests will be bilateral with alpha = 5 %.
Details of the analyzes are shown below:
Description of the population at baseline (before radiotherapy)
This description will include:
– Medical data collected in the questionnaire,
including in particular the baseline risk factors of
neurological complications.
– All biomarkers
– The MRI abnormalities
– The results of CSCT and complete cognitive
assessments.
The results will be presented for the complete sample.
Dose assessment
This reconstruction will be made for each patient based
on data from radiotherapy treatment plan. Histograms
of dose/volumes will be retrieved for each structures of
interest listed in Table 3 in order to study correlations
between anatomic regions and neuropsychological
dysfunctions.
Analysis of evaluation criteria
Based on primary endpoint definition, the estimate of
the incidence of cognitive impairment related to radio-
induced leukoencephalopathy in our cohort will be
made.
An analysis of the dose–response relationship between
radiation dose absorbed by different brain structures and
cognitive abnormalities observed after radiotherapy will
be made using a multivariate Cox model taking into ac-
count the delivered dose to the organ of interest and the
time occurrence of cognitive complications. An adjust-
ment on risk factors for cognitive complications will be
achieved. Similarly for patients with cognitive impair-
ment before radiotherapy, an analysis of potential associ-
ated risk factors will be carried out with the use of a
multivariate model.
Secondary judgments criteria, including changes in
MRI images relative to the reference imaging and
changes in series of biological markers between mea-
surements before RT, 4 weeks, 12 month and
36 months after RT, will be analyzed by parametric
distribution comparison tests (Z) or nonparametric if
needed (Wilcoxon tests).
In addition, an analysis will be conducted of the sensi-
tivity and specificity of the CSCT to demonstrate cogni-
tive impairment by comparing the CSCT performed
before radiotherapy and detailed neuropsychological as-
sessment (gold standard) achieved at the same time.
More, CSCT decay during follow-up will be analyzed by
comparing its results to formal assessment during years
after treatment, to study its sensibility in detecting cog-
nitive decrement after radiotherapy.
Time plan
Initial inclusion data collection began in April 2015 and
will continue through 2017. First statistical analysis
about cognitive impairment related to radio-induced leu-
koencephalopathy incidence will be available in the end
of 2016.
Discussion
This study should improve our knowledge on neurologic
complications of radiotherapy through an original multi-
disciplinar approach combining cognitive, biologic,
imagery and dosimetric investigations. Our primary ob-
jective is to precisely explore cognitive impairments
present before radiotherapy and to follow their worsen-
ing, or the onset of new impairments not present at
baseline, during the first years after the treatment. The
collection of data from different nature could be very
useful to understand the leukoencephalopathy process
and risk factors associated. Indeed, the assessment of
cognitive defect linked to leukoencephalopathy could be
obscured by the progression of the disease. Then, precise
assessment of the type of cognitive defect associated
with information on dose received by organs of interest
and MRI results will be a major issue to study the dose
Table 4 Biomarkers sampled in blood
Classical biomarkers correlated
with cognitive impairments
S-100B protein [GenBank : NP_006263]
8,12-iso-iPF2a-VI isoprostane
Homocysteine [GenBank : NP_060084]
microRNAs
New biomarkers brain-miR-112 [GenBank : AF480510]
brain-miR-161 [GenBank : AJ535829]
















hsa-let-7f-5p [GenBank : LM378754]
microparticles
Durand et al. BMC Neurology  (2015) 15:261 Page 6 of 9
response relationship between leukoencephalopathy de-
velopment and radiation exposure to the brain.
Chemotherapy is known to induce cognitive impair-
ments as well and produce a synergistic effect when
administrated in combination with RT [2, 12]. Unfortu-
nately, the treatment protocol received by our patient
population doesn’t allow to specifically study the partici-
pation of chemotherapy in cognitive decrement. Never-
theless, chemotherapy related impairment are assumed
to be transient [33] and not as strong as radiation-
related impairments. Moreover, neurotoxicity of chemo-
therapy is not always proved in studies investigating this
problem [34], and subjective complaints of patient seems
to be more related to emotional distress and fatigue than
to formal dysfunctions [35].
One other important goal of our project is to improve
the detection of cognitive defects at early stage. Current
formal assessment of cognitive status lasts between 1
and 2 h or more, and cannot be performed as often as
needed in this population because of an important
learning-effect. The Compurterised Speed Cognitive Test
(CSCT) is a quick cognitive assessment tool validated in
a population of patients presenting multiple sclerosis.
The CSCT just need few minutes to be performed and
appears to be a potential useful tool in the patient
follow-up [36]. This test use in the neuro-oncologic con-
text could importantly improve the detection of cogni-
tive impairments and decrement. Our study will help to
validate its use in our population by comparing the
CSCT to a more complete battery at baseline time be-
fore radiotherapy and during the follow-up after treat-
ment. Several biomarkers of neurotoxicity will be also
tested in our population in order to try to individualize
prognostic biomarkers of leukoencephalopathy.
Prospective methodology of data collection and the
choice of a homogenous population will allow us to
analyze precisely the selected outcomes, avoiding poten-
tial bias linked to retrospective studies. However, one
limit of our study is to focus only on patients with high
grade of glioblastoma, who are known to have a very
short life expectancy, with a median expected survival
being less than 18 months [37]. Nevertheless, it seems
that leukoencephalopathy could appear as soon as within
the 6 first months after radiotherapy. Furthermore, the
rather large number of included patients will allow us to
characterize cognitive defects at short and medium
term.
With a better screening and understanding of neuro-
toxicity, the treatment regiments could be adapted to
risk factors present for each patient in order to reduce
complication. More, preventive actions and cares could
be developed to reduce the burden of cognitive deficits
and preserve the quality-of-life and autonomy for patient
at risk.
Conclusion
Leukoencephalopathy is one of the most frequent mid-
to long-term complications of cranial radiotherapy.
However, its incidence is not well established and the
pathophysiology remains poorly understood. By an ori-
ginal multidisciplinary approach, the study EpiBrainRad
aims to improve knowledge about this condition to fa-
cilitate the detection and prevention of radio-induced
impairments. The main challenge is to preserve quality-
of-life after cancer treatments, which involves to study
risk factors and development of such complications.
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